Registry Study for Optimal Management of Liver Failure in the Chinese Population (RESOLVE-C)

Xi'an Jiaotong University

Status

Enrolling

Conditions

Liver Failure

Treatments

Procedure: ACLF

Procedure: SALF

Procedure: ALF

Study type

Observational

Funder types

Other

Identifiers

NCT05740696

XJTU1AF2023LSK-019

Details and patient eligibility

About

Liver failure is the most severe form of liver damage caused by viral, alcoholic, drug-related and ischemia-reperfusion factors, often combined with extrahepatic organ damage, resulting in a high mortality rate. This study intends to construct a real-world case registry database of inpatients with liver failure based on an electronic clinical data collection system through a multicenter collaborative network to study the clinical characteristics, epidemiology of bacterial and fungal infections, the impact of sarcopenia on clinical prognosis, and optimization of treatment strategies such as antiviral and artificial liver in Chinese inpatients with liver failure. The cohort and experience generated from this study will be used as a support for a series of future studies to focus on clinical issues such as infection, end-stage liver disease combined with organ failure, and early warning of critically ill patients.

Enrollment

500 estimated patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients with a diagnosis consistent with liver failure and pre-liver failure:

Extreme weakness with significant gastrointestinal symptoms such as anorexia, vomiting and abdominal distention;
Elevated alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) with progressive jaundice (TBil≥85.5 μmol/L);
Bleeding tendency with PTA ≤ 60% or INR ≥ 1.5.

Exclusion criteria